Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group

Chezi Ganzel, Svetlana Trestman, Shai Levi, Moshe E. Gatt, Noa Lavi, Iuliana Vaxman, Ory Rouvio, Hila Magen, Eyal Lebel, Netanel A. Horowitz, Merav Leiba, Tamar Tadmor, Katrin Herzog Tzarfati, Celia Surio, Shay Yeganeh, Nagib Dally, Irit Avivi, Yael C. Cohen

Research output: Contribution to journalArticlepeer-review

Abstract

Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia. In this retrospective multicenter study, 68 SP patients were included. Compared to solitary extramedullary plasmacytoma (SEP), patients with solitary bone plasmacytoma (SBP) were younger (57.3 vs. 70.9 years, p = 0.031), had larger plasmacytoma (median: 5.4 vs. 3 cm, p = 0.007) and higher median involved free light chain level (61 vs. 25.8 mg/L, p = 0.056). 92.6% of patients were treated by radiotherapy and 11.8% received systemic anti-myeloma treatment. With a median follow-up of 42 months, 45.6% of patients progressed (8.8%–recurrent SP, 36.8%–active myeloma). The median PFS was 58 months and the median OS has not been reached (10-year OS: 84.8%). Patients who received also anti-myeloma treatment had longer PFS compared to those who did not (median not reached vs. 48 months, p = 0.056). In conclusion, SBP and SEP appear to be different diseases. Radiotherapy is the cornerstone in the SP treatment. A large prospective trial is needed to evaluate the impact of adding systemic anti-myeloma treatment to local radiotherapy.

Original languageEnglish
Pages (from-to)3448-3455
Number of pages8
JournalLeukemia and Lymphoma
Volume63
Issue number14
DOIs
StatePublished - 1 Jan 2022
Externally publishedYes

Keywords

  • Solitary plasmacytoma
  • multiple myeloma
  • radiotherapy
  • solitary bone plasmacytoma
  • solitary extramedullary plasmacytoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group'. Together they form a unique fingerprint.

Cite this